Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV® (telavancin) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Mergers and Acquisitions Trading Halts

Theravance Biopharma (TBPH) Tops Q3 EPS by 5c, Revenues MissNovember 6, 2018 4:57 PM Cumberland Pharmaceuticals (CPIX) Confirms Acquisition of VIBATIVNovember 6, 2018 8:38 AM Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland PharmaceuticalsNovember 6, 2018 8:30 AM